MedicaidPrior AuthMedium impact
KMAP BULLETIN: Pharmaceutical Prior Authorization Updates – April 2026
Kansas Medicaid (KanCare)·KS·Provider Bulletin
Effective date
May 1, 2026
We identified it
Jun 21, 2026
Summary
KMAP is removing prior authorization requirements for Olezarsen (Tryngolza®) effective after April 30, 2026, while adding prior authorization requirements for 11 medications including common drugs like Amlodipine, Denosumab, Tapentadol, and others starting May 1, 2026. This affects Kansas Medicaid patients and requires billing system updates for prior authorization workflows.
Action Required
By April 30, 2026: Billing team must update prior authorization requirements in billing system - remove PA requirement for Olezarsen (Tryngolza®) and add PA requirements for Amlodipine (Sdamlo®), Denosumab-kyqq (Aukelso® and Bosaya®), Lisdexamfetamine (Arynta®), Meloxicam (Zybic®), Methocarbamol (Atmeksi®), Metoprolol tartrate 12.5 mg tablet, Plozasiran (Redemplo®), Sulfacetamide-sulfur emulsion (Labeler 73352), Tapentadol (Nucynta® and Nucynta ER®), and Tizanidine (Ontralfy®). Update encounter forms and alert providers. Monitor KMAP Open Claims Resolution Log for MCO implementation timing as it may vary from stated dates.